Junjie Cao

Dr. Junjie Cao


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2022 in Current Research in Translational Medicine
Verified
Journal Article
Closed access
JCJunjie Cao
Junjie Cao
RPRenzhi Pei
Renzhi Pei
YLYing Lu
Ying Lu
ZZZhongzheng Zheng
Zhongzheng Zheng
ZYZhiyang Yuan
Zhiyang Yuan
TWTiantian Wang
Tiantian Wang

13 February 2024 in Transfusion
Verified
Journal Article
Closed access
JCJunjie Cao
Junjie Cao
SLShaoyan Lu
Shaoyan Lu
DLDanjie Luo
Danjie Luo
RPRenzhi Pei
Renzhi Pei
YLYing Lu
Ying Lu
SLShuangyue Li
Shuangyue Li

25 October 2024 in Acta Haematologica
Verified
Journal Article
Closed access
JCJunjie Cao
Junjie Cao
XZXianxu Zhuang
Xianxu Zhuang
DLDanjie Luo
Danjie Luo
RPRenzhi Pei
Renzhi Pei
YLYing Lu
Ying Lu
XLXuhui Liu
Xuhui Liu
Introduction: The combination of venetoclax (VEN) and azacytidine (AZA) has demonstrated potential in achieving rapid and effective remissions in elderly patients with acute myeloid leukemia (AML). Allogeneic hematopoietic stem cell transplantation is a promising potential cure for high-risk AML, as VEN-based therapies have a worse prognosis in elderly patients. This study aimed to assess the efficacy of sequential haploidentical HSCT following two courses of VEN and AZA therapy in patients with AML aged 55 years and older. Methods: We conducted a retrospective study on AML patients aged 55–70 years who received intensive chemotherapy or two courses of VEN/AZA therapy, followed by haploidentical allo-HSCT (haplo-HSCT) based on disease risk degree, measurable residual disease status, and patient’s preference. Results: Between January 2019 and December 2023, 141 newly diagnosed AML patients received initial treatment with intensive chemotherapy or VEN/AZA therapy. Among them, 64 patients received haplo-HSCT, while 77 did not. The 1-year overall survival (OS) and relapse-free survival (RFS) of patients who received haplo-HSCT were significantly higher than those who did not receive haplo-HSCT (p < 0.05). Among patients who received transplantation, there was no significant difference in 1-year OS and RFS between the VEN/AZA and intensive chemotherapy groups: 76.3% versus 69.3% (p = 0.367) for OS, and 74.5% versus 69.7% (p = 0.473) for RFS. High-risk ELN stratification and the presence of ≥4 gene mutations were associated with lower OS and RFS in both univariate and multivariate analyses. Conclusions: AML patients over 55 years of age who received haplo-HSCT after two courses of VEN/AZA therapy had outcomes similar to those who received haplo-HSCT after intensive chemotherapy, suggesting that two courses of VEN/AZA therapy as a bridge to haplo-HSCT are feasible for patients over 55 years old.

15 March 2026 in Cancer Medicine
Verified
Journal Article
Open access
JYJiaojiao Yuan
Jiaojiao Yuan
JCJunjie Cao
Junjie Cao
PYPeipei Ye
Peipei Ye
TWTiantian Wang
Tiantian Wang
DCDong Chen
Dong Chen
YLYing Lu
Ying Lu
Objective: Primary poor graft function (PGF) is a common and serious complication after haploidentical hematopoietic stem cell transplantation (haplo‐HSCT). This study retrospectively evaluates the efficacy and safety of a novel combination therapy consisting of low‐dose decitabine, donor lymphocyte infusion (DLI), and eltrombopag for the treatment of primary PGF subsequent to haplo‐HSCT. Methods: In this analysis of ten patients, decitabine was administered at a dose of 7 mg/m 2 /day for three consecutive days, followed by DLI on the fifth day and eltrombopag, which was started at 50 mg/day and titrated up to 150 mg. The primary endpoints of the study encompassed hematologic recovery. Results: Nine patients (90%) achieved a complete response with normalized blood counts, while one patient (10%) showed a partial response with transfusion independence. Adverse events included manageable graft‐versus‐host disease (GVHD) in four patients. Conclusion: These findings indicate that this triple therapy represents a promising approach for the management of primary PGF following haplo‐HSCT.

20 September 2024 in Current Research in Translational Medicine
Verified
Journal Article
Closed access
JCJunjie Cao
Junjie Cao
XZXianxu Zhuang
Xianxu Zhuang
RPRenzhi Pei
Renzhi Pei
YLYing Lu
Ying Lu
PYPeipei Ye
Peipei Ye
XLXuhui Liu
Xuhui Liu

12 December 2023 in Journal of Immunotherapy
Verified
Journal Article
Closed access
JCJunjie Cao
Junjie Cao
RPRenzhi Pei
Renzhi Pei
YLYing Lu
Ying Lu
Dong ChenDong Chen
Dong Chen
XDXiaohong Du
Xiaohong Du
SLShuangyue Li
Shuangyue Li
Myeloid-derived suppressor cells (MDSC) are powerful immunomodulatory cells that play an important role in infectious and inflammatory disorders, but the correlation between graft MDSC amount and early transplant outcomes remains unknown in allogeneic hematopoietic stem cell transplantation. We collected data from 91 patients with acute leukemia undergoing haploidentical allogeneic hematopoietic stem cell transplantation. The grafts were analyzed in terms of CD34+ cells, CD3+ T cells and subpopulation, and MDSC (HLA-DR-/lowCD33+CD16-) by flow cytometry. The cutoff value of the MDSC proportion in the graft on the receiver operating curve was 8.89%, with a sensitivity of 0.833 and specificity of 0.852. Day +100 cumulative incidences of II-IV and III-IV acute graft-versus-host disease (aGVHD) in the low MDSC group were 73.5% and 38.8%, respectively, and that in the high MDSC group were 5.3% and 0%, with a significant difference in incidences of II-IV and III-IV aGVHD (P<0.001). The overall survival, relapse-free survival, and GVHD-relapse-free survival (GRFS) at 1 year were 66.3% versus 80.5% (P=0.043), 71.6% versus 71.7% (P=0.248), and 22.1% versus 62.8% (P<0.001), respectively. No significant difference in the cumulative incidence of relapse between the 2 groups was observed. Multivariate analysis revealed that higher MDSC proportions were associated with a lower risk of II-IV aGVHD. Graft MDSC proportion exceeding 8.89% was significantly associated with higher overall survival and GRFS. The prophylaxis of antithymocyte globulin+post-transplant cyclophosphamide and higher MDSC proportion in the graft were favorable factors for improving GRFS. In conclusion, graft MDSC proportion may be a significant predictor of aGVHD.